XML 47 R19.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Development Stage Supplemental Equity Disclosure | 12 Months Ended
--- | ---
Dec. 31, 2011
Development Stage Supplemental Equity Disclosure [Abstract] |
Development Stage Supplemental Equity Disclosure | 11. Development Stage Supplemental Equity Disclosure Summarized below are the Company’s equity (common stock and common stock options) transactions since the Company’s inception through December 31, 2011 (in thousands except per share data).
Type of Security |  | Date of Issuance |  | Shares of Common Stock |  |  | Dollar Amount of Consideration ($) |  |  | Price per Share or Exercise Price per Share ($) |  |  | Counter Party to Transaction |  | Nature of Non-Cash Consideration |  | Basis of Assigning Cost
Common Stock |  | April 3, 2006 |  |  | 1,624,278 |  |  |  | 2 |  |  |  | 0.002 |  |  | Founders |  | NA |  | Cash
Common Stock |  | January 8, 2007 |  |  | 7.040,318 |  |  |  | 48 | (A) |  |  | 0.007 |  |  | CytRx |  | Contributed Assets |  | Predecessor Cost
Common Stock |  | April 30, 2007 |  |  | 3,273,292 |  |  |  | 15,348 | (B) |  |  | 5.19 |  |  | CytRx |  | NA |  | Cash
Common Stock |  | April 30, 2007 |  |  | 462,112 |  |  |  | 2,311 |  |  |  | 5.00 |  |  | UMMS |  | Intellectual Properties |  | Independent Third Party Valuation
Common Stock |  | August 18, 2007 |  |  | 30,000 |  |  |  | 150 |  |  |  | 5.00 |  |  | Directors |  | — |  | Cash
Common Stock |  | September 28, 2007 |  |  | 188,387 |  |  |  | 978 |  |  |  | 5.19 |  |  | CytRx |  | NA |  | Independent Third Party Valuation
Common Stock |  | November 21, 2007 |  |  | 66,045 |  |  |  | 331 |  |  |  | 5.00 |  |  | Exercise of Stock Options |  | NA |  | Cash
Common Stock |  | June 26, 2008 |  |  | 1,073,299 |  |  |  | 7,918 |  |  |  | 8.12 |  |  | PIPE |  | NA |  | Net Cash
Common Stock |  | October 6, 2008 and November 16, 2008 |  |  | 5,500 |  |  |  | 26 |  |  |  | 5.00 |  |  | Exercise of Stock Options |  | NA |  | Cash
Common Stock |  | January 30, 2009 |  |  | 58,398 |  |  |  | NA |  |  |  | NA |  |  |  |  | NA |  | Market Value
Common Stock |  | May 1, 2009 |  |  | 281 |  |  |  | NA |  |  |  | 4.19 |  |  | Exercise of Stock Options |  | NA |  | Cash
Common Stock |  | August 3, 2009 and August 4, 2009 |  |  | 2,385,715 |  |  |  | 7,714 |  |  |  | 3.50 |  |  | Registered Direct |  | NA |  | Net Cash
Common Stock |  | March 22, 2010 |  |  | 2,700,000 |  |  |  | 15,235 |  |  |  | 6.00 |  |  | Registered Direct |  | NA |  | Net Cash
Common Stock |  | Various — 2010 |  |  | 53,500 |  |  |  | 254 |  |  |  | 4.75 |  |  | Exercise of Stock Options |  | NA |  | Cash
Common Stock |  | January 2, 2010 and February 9, 2010 |  |  | 86,634 |  |  |  | 207 |  |  |  | NA |  |  | Restricted Stock Units |  | NA |  | Market Value
Common Stock |  | March 4, 2011 |  |  | 6,000,000 |  |  |  | 7,307 |  |  |  | 1.35 |  |  | Registered Direct |  | NA |  | Net Cash
Common Stock |  | March 15, 2011 |  |  | 220,729 |  |  |  | 256 |  |  |  | 1.16 |  |  | Restricted Stock Units |  | NA |  | Market Value
Common Stock |  | April 13, 2011 |  |  | 4,974,090 |  |  |  | 6,367 |  |  |  | NA |  |  | Acquired Company |  | NA |  | Market Value
Common Stock |  | April 20, 2011 |  |  | 11,950,000 |  |  |  | 10,853 |  |  |  | 1.00 |  |  | Registered Direct |  | NA |  | Net Cash
Common Stock |  | July 1, 2011 |  |  | 18,824 |  |  |  | 15 |  |  |  | 0.83 |  |  | ESPP |  | NA |  | Cash
Common Stock |  | July 27, 2011 |  |  | 150,000 |  |  |  | 150 |  |  |  | 1.00 |  |  | Exercise of Warrants |  | NA |  | Cash
Common Stock |  | September 26, 2011 |  |  | 700,000 |  |  |  | 455 |  |  |  | 0.65 |  |  | Registered Direct |  | NA |  | Cash
Common Stock |  | December 6, 2011 |  |  | 4,151,000 |  |  |  | 3,120 |  |  |  | NA |  |  | Exchange with Warrant Holders |  | NA |  | Market Value
Common Stock |  | Various — 2011 |  |  | 599,051 |  |  |  | 594 |  |  |  | NA |  |  | Stock Compensation |  | NA |  | Market Value
(A) | Transactions between related parties are accounted for at the historical cost of CytRx, with the intellectual property which was previously expensed on CytRx’s books being recorded at zero cost and equipment and furnishings being recorded at $48,000.
(B) | The Company received gross proceeds of $17.0 million for the issuance of the 3,273,292 shares of common stock which equals $5.19 per share. The gross proceeds were reduced by a reimbursement to CytRx of (1) $1.3 million for RXi’s pro rata share of offering costs related to the April 17, 2007 private placement conducted by CytRx to fund its capital contribution to the Company and (2) $363,000 of expenses incurred on behalf of RXi for the year ended December 31, 2006. Net proceeds to RXi after these charges were $15.3 million or $4.69 a share.

X
- Definition The entire disclosure for all or part of the detailed information required for development stage enterprises. The information may also be disclosed on an element-by-element basis. Information may include an identification of the current or prior year financial statements of the entity, its development stage subsidiaries, or its investees as those of one or more development stage enterprises; a description of the nature of the development stage activities in which each enterprise is engaged; and in the first fiscal year in which each enterprise is no longer considered a development stage enterprise, a statement that in prior years the enterprise had been in the development stage. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 215 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 225 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472436&loc=d3e38614-110930 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 210 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 7 -Paragraph 11, 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 235 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38942-110933 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472471&loc=d3e38015-110924 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 235 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 215 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38313-110927 + Details
Name: | us-gaap_DevelopmentStageEnterpriseGeneralDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_DevelopmentStageEnterprisesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration